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High-throughput technologies were employed over the past decade to study the expression profiles of cells and tissues. There are 
large collections of accumulated data from public databases and numerous research articles were published on these data. In the 
current study, we performed meta-analysis on the gene expression data from human liver and kidney tissues produced from five 
different technologies: EST, SAGE, MPSS, microarray, and RNA-Seq. We found RNA-Seq was the most sensitive in the number 
of genes it detected while SAGE and MPSS were the least sensitive. For the genes detected by all the platforms, there were gener-
ally good correlations to the measured expression levels of corresponding genes. We further compared detected genes to liv-
er/kidney proteomics data from the Human Protein Atlas, and found 960 of the 8764 genes only detected by RNA-Seq were vali-
dated by proteomics results. In conclusion, RNA-Seq is a more sensitive and consistent technology compared to the other four 
high-throughput platforms, though their results are in general agreement. Average coverage was determined to be the preferred 
measurement to represent gene expression levels by RNA-Seq data and will be used in future works. 
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The transcriptome is the collection of all RNA molecules in 
one or a group of cells. Studying the transcriptome is vital 
to understanding the functions of unknown genes, to re-
vealing the regulating mechanism of specific genes, and 
also to researching the diagnosis and treatment of some 
diseases [1–3]. In the last few years, with the development 
of microarray and sequencing technologies, transcriptome 
research has become faster and more accurate. 
Several technologies have been developed to study the 
transcriptome, namely EST, SAGE [4], MPSS [5], microar-
ray, and RNA-seq. ESTs are short sequences of cDNA 
fragments (usually 200–800 nucleotides long), which have 
been used in gene discovery [6] and gene sequence deter-
mination [7]. SAGE allows fast and detailed analysis of 
thousands of transcripts. As it does not require a known 
template clone, SAGE can be used to recognize and quanti-
tate new genes, and it has been successfully used to describe 
the transcriptome of various diseases and most organisms 
[8,9]. MPSS is a gene expression quantification approach 
and has high sensitivity and absolute gene expression alt-
hough it is confined to restriction enzyme recognition site 
[10]. Microarray-based gene expression profiling can be 
used to measure changes in gene expression levels and to 
genotype or re-sequence mutant genes, etc [11]. 
RNA-Seq [12], uses next-generation sequencing tech-
nologies to sequence all cDNAs from a sample. Because of 
its high throughput, RNA-Seq can provide more compre-
hensive information on the transcriptome than the four 
methods above [1]. RNA-Seq can be used to detect the 
overall transcriptional activities of many species at the level 
of single nucleotides [13], discover unknown or rare tran-
scripts [14,15], and recognize alternative splicing sites [16] 
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or cSNP [17] accurately. Furthermore, RNA-Seq can be 
performed with different platforms to deal with different 
problems, as they have different advantages. For example, 
using the Illumina Genome Analyzer platform, recent ap-
plications include sequencing mammalian transcriptomes 
[18], ABI Solid Sequencing to profile stem cell transcrip-
tomes [13] or Life Science’s 454 Sequencing to discover 
SNPs [19]. Even though each platform has its technical in-
dividualities, the information gathered from each is of the 
same nature. 
Early technologies were limited by the size of reads, such 
as ESTs, or the cost, like MPSS and SAGE, or the through-
put, as microarray. However, these limiting features are 
precisely the advantage of RNA-Seq. In this work, we 
compared these five technologies in a study of transcrip-
tomes from two tissues, liver and kidney, to assess the sen-
sitivity and reproducibility. Comparative analysis was per-
formed with the historic research data to investigate how 
data from these five technologies are correlated. 
1  Methods 
1.1  RNA-Seq 
The raw RNA-Seq data were obtained from the Sequence 
Read Archive (SRA) of NCBI with accession number 
SRA000299. Data for each tissue contains three datasets, 
SRR002321, SRR002322 and SRR002323 for liver, 
SRR002320, SRR002324 and SRR002325 for kidney. The 
original tissue samples were from the liver and kidney tis-
sues of one normal human male dead less than 6 h. All 
cDNA samples were sequenced by the Illumina Solexa 
platform [20]. 
The length of each read is 36 bp. The reads were mapped 
to the UniGene data, in which alternatively spliced tran-
scripts were removed, by using the alignment software 
MAQ [21]. Two or less mismatches were allowed in the 
mapping process. The genes that mapped to at least one 
read were considered as potentially expressed. After map-
ping to the reference data, the amount of coverage at each 
position of a gene can be calculated through the alignment 
result. 
In this work, we used two standards, average coverage 
and max depth for the measurement of gene expression. The 
average coverage indicates the normalized coverage based 
on gene length, and the max depth shows the largest depth 
position of one gene. 
1.2  Microarray 
Microarray data on liver tissue were from the Chinese Hu-
man Liver Proteome Project (CNHLPP) [22]. The raw RNA 
samples from ten liver tissues were hybridized to HG- 
U133plus 2.0 high-density oligonucleotide arrays in two 
technical replicates. Then, using GENECHIP 3.2 to perform 
the primary image analysis of the arrays, we collected three 
series of human liver-related gene expression data (platform: 
GPL570; Series: GSE11045, GSE7117, GSE7741). Micro-
array data on kidney tissue was acquired from the GEO da-
tabase of NCBI (platform: GPL570; Series: GSE11045, 
GSE11151, GSE12606). 
The data from livers were then filtered according to the 
Present (P) versus Absent (A) call percentage using MAS 
5.0 algorithm [23] and the statistical software R (http:// 
www.r-project.org/). The genes that were mapped to at least 
one present probe set were considered as expressed. The 
probe sets from kidneys were mapped to Ensembl genes. If 
only a single probe set was mapped to a gene then the cor-
responding intensities were used in all future analyses. If 
multiple probe sets mapped to the same gene then the probe 
set that was most often called as present was considered. If 
two or more probe sets were called present in the same 
number of hybridizations then a probe set at random was 
chosen and used in all further analyses. 
1.3  Other datasets 
The EST data were all acquired from dbEST. The SAGE 
data were a subset of Human SAGE Genie data from the 
CGAP website (http://cgap.nci.nih.gov/). The MPSS data 
were produced from experiments performed by TaKaRa Co., 
Japan using CNHLPP samples, and the data can be down-
loaded from the website (http://202.127.18.238/hepatocytes/) 
[24]. The expression data of proteins in normal human tis-
sues were obtained from the Human Protein Atlas database 
[25].  
In our work, we determined the overriding significance 
of RNA-Seq by comparing results from different methods 
with sampling errors. RNA-Seq datasets have biological 
repeats, some microarray data have technical repeats, and 
others are from public databases. The details of the data 
used in this work can be found in Supporting Information 
S5. 
1.4  Correlation coefficient 
The strength of the linear association between two variables 
is quantified by the correlation coefficient. Given a set of 
observations (x1, y1), (x2, y2), …, (xn, yn), the formula for 





x x y y
r
n s s
            (1) 
2  Results 
2.1  Study design and data collections: EST, SAGE, 
MPSS, microarray, and RNA-Seq 
In this study, we compare the gene expression data of liver 
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and kidney tissues from five different platforms, RNA-Seq, 
microarray, EST, SAGE, and MPSS. All the original data 
were acquired from public databases. The raw data of RNA- 
Seq consist of 88055898 reads from liver with 18301710 
reads mapped to the reference, and 83696940 reads from 
kidney with 17968282 reads mapped to the reference (Table 
1). In the MPSS, SAGE or EST dataset, the gene which 
contains at least one scanned sequence was considered as 
expressed while in the microarray dataset, the gene should 
contain at least one present probe. In total, we found 24272 
genes expressed in liver tissue and 24694 genes expressed 
in kidney tissue. In the 24272 candidate genes of liver, 
21210 genes came from RNA-Seq data, 12821 genes from 
microarray data, 12152 genes from EST data, 6413 genes 
from MPSS data, and 6780 genes from SAGE data. In the 
24694 candidate genes of kidney, 21759 genes were derived 
from RNA-Seq data, 12900 genes from microarray data, 
14093 genes from EST data, 5821 genes from MPSS data, 
and 6621 genes from SAGE data (Figure 1 and Table 1). 
There are in total 3047 unique genes detected from all 
five datasets from liver and 2517 unique genes from kidney. 
Interestingly, over 5000 genes were detected as expressed  
Table 1  The number of genes of two tissues, liver and kidney, detected 
by five high-throughput transcriptome technologies 
 Liver Kidney 
RNA-Seq  21210 21759 
Microarray  12821 12900 
EST  12152 14093 
MPSS  6413 5821 
SAGE 6780 6621 
Total 24272 24694 
 
Figure 1  Number of genes of two tissues, liver and kidney, detected by 
five high-throughput transcriptome technologies. There are in total 25905 
genes in the reference data after removing alternatively-spliced transcripts. 
From RNA-Seq data, 21210 genes for liver and 21759 genes for kidney 
were detected as expressed, while less than 15000 genes were detected by 
the other four technologies. 
from the RNA-Seq dataset and, in comparison, less than 
300 genes were detected from the other datasets (Figure 2). 
2.2  Comparison of gene expression data between mi-
croarray and RNA-Seq data 
We compared RNA-Seq with microarray datasets, as they 
are currently the two most popular technologies for tran-
scriptome studies. We compared commonly and differently 
detected genes between microarray and RNA-Seq. Almost 
97% of the genes identified by microarray can also be de-
tected by RNA-Seq (Figure 3), and about 9000 genes from 
the RNA-Seq dataset cannot be detected by microarray. 
Therefore, we mapped the sequences of microarray probes 
to the UniGene reference data. Of the 25905 genes in the 
reference data, 21883 genes can be mapped by microarray  
 
Figure 2  Venn diagrams describing the number of expressed genes de-
tected by five high-throughput transcriptome technologies from liver and 
kidney. A stands for RNA-Seq, B for microarray, C for EST, D for MPSS, 
and E for SAGE. 
 Ping J, et al.   Chin Sci Bull   August (2012) Vol.57 No.22 2923 
 
Figure 3  Venn diagrams representing the number of genes detected by 
RNA-Seq and microarray from liver and kidney tissues. 
probes. Respectively, 2093 genes of liver and 2309 genes of 
kidney cannot be mapped by probes. According to the re-
sults, those un-detected genes from microarray data, in-
cluding non-probe-mapped genes and probe-mapped genes 
without expression signals, can be detected by the RNA-Seq 
method and have relatively lower expression signals (Figure 
4). The detecting range of RNA-Seq is significantly larger 
than the microarray technique. 
Then expression intensities of each gene were compared, 
using two different standards of RNA-Seq data and absolute 
intensities of microarray data (Figure 5). These two inde-
pendent measures of gene expression are highly correlated, 
especially the highly expressed genes. We compared the 
distribution and characteristics of commonly and differently 
detected genes between microarray and RNA-Seq data 
(Figure 6). The genes called by both methods expressed 
significantly more highly than those detected only from 
RNA-Seq data. The expression values of the genes called by 
both methods are symmetrically distributed while most of 
the expression values of the genes only detected by RNA- 
Seq were lower. Moreover, from Figures 5 and 6, it can be 
found that average coverage is more appropriate than max 
depth as a standard, for the expression intensities are more 
correlative and the distribution is more symmetrical.  
2.3  Comparison of gene expression data between MPSS 
and RNA-Seq, ESTs and RNA-Seq, and SAGE and RNA- 
Seq data 
The gene expression data were analyzed and compared be-
tween MPSS and RNA-Seq, between ESTs and RNA-Seq, 
and between SAGE and RNA-Seq (Figures S1–S9). There 
were 9244 and 7820 more genes detected by RNA-Seq than 
by ESTs from liver and kidney, respectively (Figure S1).  
 
Figure 4  Boxplots summarizing the distribution of the expression values from RNA-Seq data. A represents the genes which cannot be detected from mi-
croarray data but can be mapped by probe sequences and can be called from RNA-Seq data. B represents the genes which cannot be detected from microar-
ray data or mapped by probe sequences but can be called from RNA-Seq data. C represents the non-probe-mapped genes that can be detected only from 
RNA-Seq. 
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Figure 5  Comparing the gene expression values from RNA-Seq data and microarray data of liver and kidney tissues. In the top two diagrams, the X-axis 
indicates the Log2 transformed expression values using average coverage as the standard. The corresponding Log2 transformed expression values from mi-
croarray data of the each gene is plotted on the Y-axis. In the lower two diagrams, the X-axis indicates the Log2 transformed expression values from 
RNA-Seq data use max depth as the standard. 
 
Figure 6  Boxplots summarizing the distribution of the gene expression values from RNA-Seq and microarray data. In each panel, the left box shows the 
expression data of genes which were only detected from RNA-Seq data, not microarray; the data detected from both RNA-Seq and microarray data is pre-
sented in the middle box, and the right box shows all gene expression values detected from RNA-Seq data. In the top two diagrams, the Y-axis indicates the 
expression values (Log2) using average coverage as the standard and in the bottom two diagrams using max depth as the standard.  
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The high sensitivity of RNA-Seq was even more obvious 
when compared to SAGE and MPSS (Figures S4 and S7). 
There are significant correlations in the measured expres-
sion levels of corresponding genes between RNA-Seq and 
the other platforms. They are; however, lower than the cor-
relation between microarray and RNA-Seq. 
2.4  Relationship between transcriptome and proteome 
To investigate the relationship between the transcriptome 
and proteome, we used the Human Protein Atlas dataset to 
study the correlation between the genes expressed at the 
protein level and those expressed at the mRNA level in both 
liver and kidney. All genes with strong, high, medium or 
moderate intensity in the Human Protein Atlas dataset were 
labeled as “protein expressed”, while those with negative, 
low or weak intensity were labeled as “protein unexpressed”. 
There were 4304 and 3227 proteins detected from liver and 
kidney, respectively, in the Human Protein Atlas (Figure 7). 
Of those, 3964 (92.1%) and 3011 (93.3%) from liver and 
kidney, respectively, were found in RNA-Seq with corre-
sponding gene sequences. More interestingly, only 960 pro-
teins (22.3%) found in the liver proteome were detected by 
RNA-Seq. For the kidney, only 703 (21.8%) proteins were 
detected by RNA-Seq. 
3  Discussion 
In this study, we present a comparative analysis of gene 
expression in the transcriptome of liver and kidney tissues 
by utilizing data from five different technologies, ESTs, 
MPSS, SAGE, microarray and RNA-Seq. In our study, 
3047 genes in liver and 2517 genes in kidney were detected 
as expressed genes using all five technologies (Figure 2). 
RNA-Seq could identify an additional 5629 genes in liver 
and 5440 genes in kidney over the 15581 liver- and 16319 
kidney-expressed genes detected by all of the other four 
technologies. Each of the other four platforms could detect 
very few unique genes. 
In previous studies, only one-third or one-half of the 
genes were detected as expressed in one tissue. The number 
of genes detected by microarray, ESTs, MPSS and SAGE 
was limited by the detection sensitivity of these traditional  
 
Figure 7  Boxplots summarizing the distribution of protein expression data. The Y-axis indicates the Log2 transformed expression intensity of average 
coverage and max depth. A represents the genes which can be detected from both RNA-Seq and microarray data. B represents the genes which are expressed 
in the Human Protein Atlas data but cannot be mapped by probe sequences from those detected from both RNA-Seq and microarray data. C represents the 
genes which can be mapped by probe sequences from those detected from both RNA-Seq and microarray data but are not expressed in the Human Protein 
Atlas data.  
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methods. For example, HG-U133plus 2.0 high-density oli-
gonucleotide arrays contain 54675 probe sets representing 
only 19164 human genes. However, the RNA-Seq tech-
nique provides a whole genome scanning method for gene 
expression including unknown genes and transcripts. The 
high sensitivity and accuracy (Figures 2 and 3) in detecting 
those genes that have very low expression levels is one of 
the greatest advantages of RNA-Seq. 
We compared five different technologies in the study of 
tissue transcriptomes. One important challenge for four of 
the traditional technologies is to acquire enough tags from 
the overall transcripts. ESTs are small segments from 200 to 
800 bp, SAGE uses short sequences tags (10–14 bp) to iden-
tify transcripts [4], MPSS uses signature sequence tags (about 
16–20 bp) [5], and microarray probes are special sequences 
of particular known genes. Deep sequencing of RNAs 
(RNA-Seq) is a useful tool to characterize and quantify 
transcriptomes [1]. Compared with traditional techniques, 
the advantages of RNA-Seq include the following: owing to 
the high-throughput of next-generation sequencing, the cov-
erage and depth of RNA-Seq data are significant higher than 
ESTs, SAGE and MPSS sequencing; furthermore, the abil-
ity to identify novo transcripts should be highlighted when 
compared with the microarray technique. The number of 
genes detected by each technology provides evidence. 
When considering the probe sequences and gene expression 
data at the protein level, the probe sequences of the micro-
array in use might not have wide coverage. The non-probe- 
mapped genes also can be detected as expressed at the pro-
tein level (Figure 7). 
In addition, we evaluated the performance of two meas-
urement standards for the expression of genes detected by 
RNA-Seq: average coverage and max depth. The results 
indicate that the measurement of average coverage was 
more continuous than that of max depth and had stronger 
correlations with the results of the other four methods. 
Therefore, we will use average coverage as the standard to 
measure gene expression levels from RNA-Seq data in fu-
ture studies. We also compared the widely used index of 
expression level, RPKM [26], with our two indexes. The 
results using RPKM were highly consistent with each of our 
two indexes (Supporting Information S6). Considering the 
good performance of our index with low expressing genes 
and their low computational complexity, these two meas-
urement indexes are more suitable for biologists to perform 
a rough estimate of gene expression levels from RNA-Seq 
data. 
Using the genes detected by different technologies and 
their expression values, we found RNA-Seq was the most 
sensitive in terms of the number of genes it detected while 
SAGE and MPSS were the least sensitive. For the genes 
detected by all other platforms, there were generally good 
correlations in the measured expression levels of corre-
sponding genes. It is likely that sample differences were 
responsible for the few genes that were not detectable by 
RNA-Seq. In our work, we have used different experimental 
data or data from different public databases to compare five 
different platforms for tissue gene expression. As the ex-
perimental samples are not the same and the experiments 
are not performed by same lab at the same time, we have 
reason to infer that there is sample error. In addition, sam-
ples from RNA-Seq datasets are biological repeats while 
microarray data contains technical repeats from the same 
library (Supporting Information S5). For this reason, our results 
contain sampling errors and have overriding significance. 
Our findings highlight that many liver and/or kidney ex-
pressed genes, which had not yet been identified in traditional 
techniques, were detected by the RNA-Seq technique. This 
is particularly important since most of them are highly as-
sociated with biological functions of the liver and/or kidney. 
FLT3, detected only by RNA-Seq in the liver, encodes a 
class III receptor tyrosine kinase that regulates hematopoie-
sis [27]. FLT3-ligand (FL) is important for the proliferation 
and differentiation of human hematopoietic progenitors both 
in vivo and in vitro, and FL administration significantly in-
duces an antitumor effect and inhibits liver metastases [28]. 
ENTPD8, also known as NTPDase8, detected only by 
RNA-Seq, also plays an important role in liver function [29]. 
It is the liver canalicular ecto-ATPase/ATPDase and is re-
sponsible for the main NTPDase activity in liver [29]. 
CDH16 is a member of the cadherin superfamily and is ex-
pressed exclusively in the kidney [30] was also detected by 
RNA-Seq only. The connection of CDH16 to the cytoskel-
eton is important for maintaining tissue integrity in the kid-
ney, which relies on the interaction of CDH16 with alpha 
B-crystallin [31]. RhCG is a member of an ammonia trans-
porter family and plays a critical role in ammonium han-
dling and pH homeostasis in the human kidney [32]. Ac-
cording to Brown’s work, under normal conditions RhCG is 
the major putative ammonia transporter expressed in the 
human kidney [33]. The expression of RhCG was also only 
detected with RNA-Seq data. 
4  Conclusion 
The major significance of our work is that, by performing a 
meta-comparison analysis of five different technologies, we 
found RNA-Seq had the highest number of genes detected 
as expressed in two tissues and that it is sufficiently substi-
tutable for the other four technologies. Our work provided a 
technical framework for the analysis of expressed genes, the 
correlation of gene expression and provided a catalog of 
expressed genes in the liver and kidney. The integrated tis-
sue transcriptome data should provide a valuable resource 
for the in-depth understanding of human tissues and diseases. 
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S1  Comparison of gene expression data between EST and RNA-Seq data 
Figure S1  Venn diagrams representing the number of genes detected by RNA-Seq data (left cycle) and EST data (right cycle) for liver and kidney.  
Figure S2  Comparing the gene expression values from RNA-Seq data and EST for liver and kidney.  
Figure S3  Boxplots summarizing the non-parametric distribution of the expression values from RNA-Seq data comparing with that from the EST data 
for liver and kidney.  
 
S2  Comparison of gene expression data between MPSS and RNA-Seq data 
Figure S4  Venn diagrams representing the number of genes detected by RNA-Seq data (left cycle) and MPSS data (right cycle) for liver and kidney.  
Figure S5  Comparing the gene expression values from RNA-Seq data and MPSS for liver and kidney.  
